As a result, more recent efforts have focused on early-phase dynamic tumour profiling using intraoperatively, intravenously administered ICG with comparative analysis of fluorescence in healthy and unhealthy tissue over time using computer vision and artificial intelligence, while other approaches have involved advancing cell targeted agents (such as folate-receptor targeting and tumour-vessel targeting agents such as nerve growth factor-tumour necrosis factor (NGR-TGF)) for similar effect [24,25]. The gene discussed is NGF; the disease is neoplasm.